Event Title

Understanding the Role of RB-Binding Protein KDM5A in Cancer Cell Proliferation

Session Number

A07

Advisor(s)

Elizaveta Benevolenskaya, University of Illinois at Chicago

Location

Room B-101

Start Date

28-4-2016 8:25 AM

End Date

28-4-2016 8:45 AM

Disciplines

Biochemistry

Abstract

The retinoblastoma protein (pRB) is a key regulating protein in the cell cycle, which often interacts with the lysine (K)-specific demethylase 5A (KDM5A). While pRB has been shown to play a significant role in the processes of cell differentiation and metabolism, the role of KDM5A in these cellular processes is not fully known. Our investigation focused on clarifying the role of KDM5A in a non-small cell lung cancer line under different concentrations of erlotinib, a common chemotherapy drug, by examining the cell cycle and cell proliferation using the Celigo Imaging Cytometer. Cell cycle analysis revealed that there was a greater number of cells with KDM5A knocked down in the G2/M phase of the cell cycle when compared to the control, while there were fewer cells with overexpression of KDM5A in G2/M phase when compared to its respective control. Results from cell proliferation data showed that cells with knock down of KDM5A had decreased cell proliferation compared to their control at a drug concentration of 0.01 micromolar. Consistent with this result, cells with overexpression of KDM5A compared to their control did not decrease in proliferation. These findings establish that KDM5A is a potential therapeutic target for cancer treatment.


Share

COinS
 
Apr 28th, 8:25 AM Apr 28th, 8:45 AM

Understanding the Role of RB-Binding Protein KDM5A in Cancer Cell Proliferation

Room B-101

The retinoblastoma protein (pRB) is a key regulating protein in the cell cycle, which often interacts with the lysine (K)-specific demethylase 5A (KDM5A). While pRB has been shown to play a significant role in the processes of cell differentiation and metabolism, the role of KDM5A in these cellular processes is not fully known. Our investigation focused on clarifying the role of KDM5A in a non-small cell lung cancer line under different concentrations of erlotinib, a common chemotherapy drug, by examining the cell cycle and cell proliferation using the Celigo Imaging Cytometer. Cell cycle analysis revealed that there was a greater number of cells with KDM5A knocked down in the G2/M phase of the cell cycle when compared to the control, while there were fewer cells with overexpression of KDM5A in G2/M phase when compared to its respective control. Results from cell proliferation data showed that cells with knock down of KDM5A had decreased cell proliferation compared to their control at a drug concentration of 0.01 micromolar. Consistent with this result, cells with overexpression of KDM5A compared to their control did not decrease in proliferation. These findings establish that KDM5A is a potential therapeutic target for cancer treatment.